Cytomegalovirus retinitis: new developments in prophylaxis and therapy.
Jacobson
M A
MA
University of California, San Francisco, USA.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D000077404:Cidofovir; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000517:prevention & control*; D003596:Cytosine / Q000031:analogs & derivatives; D004359:Drug Therapy, Combination; D017245:Foscarnet / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds
D000998:Antiviral Agents; D015415:Biomarkers; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D015774:Ganciclovir